IR Overview

Webcast ImageWebcast
Adaptimmune to discuss updated data from 2018 ASCO annual meeting (Live)
06/04/18 at 8:00 a.m. ET
Adaptimmune to discuss updated data from 2018 ASCO annual meeting
Monday, June 4, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.


SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.

$13.200.00 (0.00%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume0
Today's Open$0.00
Previous Close$13.20
Data as of 05/23/18 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
05/16/18Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois. Data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS) will be presented during an oral presentation by Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center. G... 
Printer Friendly Version
05/09/18Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORD, United Kingdom, May 09, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the f... 
Printer Friendly Version
04/25/18Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before the open of the U.S. markets on Wednesday May 9, 2018. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day. The press release and the live webcast of the co... 
Printer Friendly Version
04/16/18Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
- Preclinical testing raises no safety concerns for MAGE A4 - - Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity - PHILADELPHIA, Pa. and OXFORD, United Kingdom, April 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the annual AACR meeting at McCormick Place in Chicago,... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/04/18 8:00 a.m. ET
Adaptimmune to discuss updated data from 2018 ASCO annual meeting
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.